礼来公司周三预计2026年利润将超华尔街预期，该全球市值最高药企押注旗下肥胖症药物需求激增，同 时公司筹备于今年晚些时候推出口服减肥药。 责任编辑：李肇孚 礼来公司周三预计2026年利润将超华尔街预期，该全球市值最高药企押注旗下肥胖症药物需求激增，同 时公司筹备于今年晚些时候推出口服减肥药。 公司股价在盘前交易中上涨近7%。 公司股价在盘前交易中上涨近7%。 得益于爆款减肥药泽布替尼的热销，以及正转向自费模式和远程医疗渠道、规模快速扩张的肥胖症市 场，礼来去年成为首家市值突破1万亿美元的制药企业。 礼来的乐观业绩展望，与其竞争对手诺和诺德形成鲜明反差。诺和诺德此前预计今年销售额将大幅下 滑，引发投资者恐慌，且已预警2026年将面临"前所未有的"价格压力。 该药企公告显示，本季度摊薄后每股收益为7.54美元。伦敦证券交易所集团汇编数据显示，分析师此前 预期值为6.67美元。 礼来预计，今年调整后每股收益将达33.50至35美元，高于分析师平均预期的33.23美元。 礼来的乐观业绩展望，与其竞争对手诺和诺德形成鲜明反差。诺和诺德此前预计今年销售额将大幅下 滑，引发投资者恐慌，且已预警2026年将面临"前所未有的" ...

February 4, 2026 For release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; (317) 416-4363 (Media) Mike Czapar; czapar_michael_c@lilly.com; (317) 617-0983 (Investors) Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance INDIANAPOLIS, February 4, 2026 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth-quarter of 2025 and provided 2026 financial guidance. "2025 was an important year for Lilly," said David A. Ricks, Lilly's c ...

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance. ...

Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. Lilly also expected adjusted ea ...

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, as it expects strong demand for its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro, to offset pricing pressures in the U.S., its largest market. ...

Core Insights - Eli Lilly and Company reported significant financial growth in Q4 2025, with a 43% increase in revenue to $19.3 billion compared to Q4 2024, driven by strong volume growth from key products like Mounjaro and Zepbound [3][4][8] - The company provided optimistic financial guidance for 2026, projecting revenue between $80 billion and $83 billion and non-GAAP EPS in the range of $33.50 to $35.00 [25][26] Financial Results - Q4 2025 revenue reached $19.3 billion, a 43% increase from $13.5 billion in Q4 2024, with a 46% increase in volume offset by a 5% decrease in realized prices [4][8] - Net income for Q4 2025 was $6.6 billion, up 50% from $4.4 billion in Q4 2024, with reported EPS increasing by 51% to $7.39 [11][15] - Non-GAAP net income for Q4 2025 was $6.8 billion, a 41% increase from $4.8 billion in Q4 2024, with non-GAAP EPS rising by 42% to $7.54 [14][37] Revenue Breakdown - U.S. revenue increased by 43% to $12.9 billion, driven by a 50% increase in volume, primarily from Zepbound and Mounjaro [5][8] - International revenue also rose by 43% to $6.4 billion, with a 38% increase in volume, largely attributed to Mounjaro [6][8] Key Product Performance - Mounjaro revenue surged by 110% to $7.4 billion in Q4 2025, with U.S. revenue at $4.1 billion, reflecting strong demand [18] - Zepbound revenue increased by 123% to $4.3 billion in Q4 2025, driven by heightened demand [19] - Verzenio revenue saw a modest increase of 3% to $1.6 billion, with U.S. revenue declining by 4% [20] Regulatory and Pipeline Developments - Regulatory advancements included FDA approvals for Kwikpen for tirzepatide and expanded indications for Jaypirca, along with submissions for orforglipron for obesity [8][21] - Positive Phase 3 trial results were reported for Taltz and Zepbound in treating psoriatic arthritis and obesity [23] Operational Expenses - Research and development expenses rose by 26% to $3.8 billion, representing 20% of revenue, reflecting ongoing investments in the product pipeline [9] - Marketing, selling, and administrative expenses increased by 29% to $3.1 billion, driven by promotional efforts for product launches [10] Gross Margin and Tax Rate - Gross margin for Q4 2025 was $15.9 billion, a 43% increase, with a gross margin percentage of 82.5% [9][12] - The effective tax rate for Q4 2025 was 19.7%, up from 12.5% in Q4 2024, influenced by a less favorable jurisdictional mix of earnings [10][13]

Financial Data and Key Metrics Changes - Consolidated revenue increased by 26% to $83.9 million, driven by double-digit growth in both distribution and service segments [5][10] - Consolidated gross profit grew by 28%, with gross margins expanding by 60 basis points [5][10] - Adjusted EBITDA rose by $2.2 million or 27.2% to $10.1 million, with a slight margin expansion [5][13] - Net loss decreased to $1.1 million, influenced by higher amortization and interest expenses [11] Business Line Data and Key Metrics Changes - Service revenue grew by 29%, with organic growth of 7%, supported by acquisitions [10] - Distribution revenue increased by 20%, driven by strong demand in rentals and product sales, with gross margin expanding by 330 basis points [9][10] Market Data and Key Metrics Changes - Strong demand observed in regulated end markets such as life sciences, aerospace and defense, and energy [5][6] - The service segment continues to show substantial growth potential, both organically and through acquisitions [9] Company Strategy and Development Direction - The company aims to leverage its acquisitions to expand geographic footprint and technical capabilities, focusing on capturing sales and cost synergies [6][16] - Investments in leadership, technology, and process improvement are expected to enhance competitive differentiation [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining high single-digit organic service revenue growth expectations for the fourth quarter [15] - The company is well-positioned for future growth, with a strong acquisition pipeline and a focus on recurring revenue streams [16][50] Other Important Information - The CEO succession plan is nearing completion, with a search committee evaluating candidates [11][58] - Additional one-time expenses related to the CEO search are expected in the fourth quarter [60] Q&A Session Summary Question: Drivers of service segment growth - Management highlighted the ramp-up of delayed service orders and strong performance in regulated markets as key drivers [19][24] Question: Impact of startup costs on margins - Management indicated that startup costs are not significant but affect margins temporarily as new customers are onboarded [21][22] Question: Distribution segment performance and AI opportunities - Management noted strong execution in distribution, particularly in power generation markets, and emphasized the potential for recurring calibration opportunities [25][26] Question: Expectations for Q4 service growth - Management reaffirmed guidance for high single-digit growth in Q4, with a strong pipeline for new business [32] Question: M&A strategy and geographic expansion - Management discussed gaps in geographic presence, particularly in Northern California, Dallas, Atlanta, and the Mid-Atlantic region, and highlighted recent expansion in Ireland [34][36] Question: Long-term growth outlook in life sciences and defense - Management acknowledged that onshoring of manufacturing in regulated spaces is beneficial and that increased defense spending presents opportunities for calibration services [49][51]

Eli Lilly and Co. (NYSE:LLY) is set to report fourth-quarter earnings on Feb. 4 before the opening bell, with Wall Street forecasting a significant revenue beat driven by its blockbuster weight-loss and diabetes drugs.While topline expectations are high, surging research costs could challenge the company's ability to hit ambitious profit targets.Revenue Expectations Vs. GuidanceAnalysts project fourth-quarter revenue of $17.90 billion, as per Benzinga, a figure that exceeds the implied ceiling of management ...

Core Viewpoint - The expectation that the global market for obesity drugs would reach $150 billion in the next decade is becoming uncertain due to falling prices for GLP-1 treatments in the U.S. [1] Group 1: Market Expectations - Wall Street's long-held expectation for the obesity drug market is now in question [1] - The anticipated market size of $150 billion may not be achievable as previously thought [1] Group 2: Pricing Trends - U.S. prices for GLP-1 treatments are experiencing a decline [1] - The price drop could significantly impact revenue projections for companies involved in obesity drug development [1]

Core Viewpoint - Tyligand Bioscience has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [3]. Company Overview - Tyligand Bioscience, established in 2017, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies [4]. - The company holds 97 patents and patent applications, including 25 related to its core product TSN1611 [4]. - Tyligand has not yet received any marketing approval for its candidate drugs and has not generated any revenue from product sales [4]. - The company is headquartered in Suzhou and employs a total of 64 staff, with 49 in research and development [4]. Shareholding Structure - Key shareholders include Dr. Tony Yantao Zhang, Dr. Boyu Zhong, Dr. Zhong-Yin Zhang, and Tyligand Holdings, collectively holding 24.01% of the issued shares [4]. - Dr. Tony Yantao Zhang directly holds approximately 0.35%, while Tyligand Holdings holds about 23.66%, with ownership distributed among the founders [4]. Management Team - Dr. Tony Yantao Zhang, 64, is the Chairman and CEO, responsible for overall management and strategic planning [5]. - Dr. Boyu Zhong, 63, serves as the Executive Director and President, leading research and development efforts [6]. Financial Performance - The company's revenue for 2023, 2024, and the first nine months of 2025 is projected to be 7.856 million, 1.506 million, and 11.358 million respectively, with losses of 70.461 million, 28.354 million, and 123 million [7]. - Revenue sources include providing research and development services and intellectual property licensing [7].